U.S. Energy Services Stock News

NasdaqGS:VISN
NasdaqGS:VISNCommunications

Vistance Networks (VISN) Valuation After Profitability Turnaround And High Profile Wi Fi 7 Stadium Deployment

Vistance Networks (VISN) is back in focus after reporting fourth quarter and full year 2025 results that shifted prior losses into net income and after showcasing a high profile Wi Fi 7 deployment at BMO Stadium. See our latest analysis for Vistance Networks. The recent move into profitability and the high profile Wi Fi 7 rollout have arrived during a softer period for the shares, with a 30 day share price return of a 7.11% decline and a 90 day share price return of a 12.36% decline. However,...
NasdaqGS:CASY
NasdaqGS:CASYConsumer Retailing

Casey’s General Stores Q3 Net Margin Expansion Tests High P E Bull Case

Casey’s General Stores (CASY) has put up another detailed scorecard for Q3 2026, with revenue of US$3.9 billion, basic EPS of US$3.51 and net income of US$130.1 million, while same store sales growth landed at 0.4%. The company has seen quarterly revenue move between US$3.9 billion and US$4.6 billion over the last few periods, with EPS ranging from US$2.35 to US$5.80 and trailing twelve month EPS at US$17.52 alongside net income of US$650.1 million. This sets the stage for investors to focus...
NasdaqGS:DBX
NasdaqGS:DBXSoftware

Assessing Dropbox (DBX) Valuation As Shares Show Mixed Short And Long Term Returns

Event context and recent share performance Dropbox (DBX) has drawn investor attention recently as its shares show mixed returns, with a gain over the past month but declines over the past 3 months and year to date. See our latest analysis for Dropbox. At a share price of US$26.40, Dropbox’s recent 30 day share price return of 5.6% contrasts with a 90 day share price decline of 2.9%. Its 3 year total shareholder return of 35.0% suggests momentum has built more over the longer term than in the...
NasdaqGS:RPRX
NasdaqGS:RPRXPharmaceuticals

The Bull Case For Royalty Pharma (RPRX) Could Change Following Asia Leadership Hire To Target Biotech Royalties

Royalty Pharma plc has appointed Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026, to lead its royalty business from Hong Kong after his prior role heading Asia Pacific Healthcare Investment Banking at Morgan Stanley. This hire positions Royalty Pharma to pursue royalty opportunities tied to Asia’s expanding biotechnology and licensing activity, including the very large 2025 Chinese medicine out‑licensing market, by building a dedicated regional platform. We will now...
NasdaqGS:GLNG
NasdaqGS:GLNGOil and Gas

The Bull Case For Golar LNG (GLNG) Could Change Following 2025 Earnings, Dividend Hike And Buybacks

In late February 2026, Golar LNG Limited reported fourth-quarter 2025 revenue of US$132.81 million and net income of US$10.36 million, alongside full-year 2025 revenue of US$393.52 million and net income of US$65.68 million, declared a US$0.25 per share dividend payable in March 2026, and confirmed completion of a share buyback totaling 4,675,710 shares for US$117.32 million. Together, the stronger year-on-year financial results, cash return through dividends, and reduced share count from...
NasdaqGS:AFRM
NasdaqGS:AFRMDiversified Financial

Is Affirm Holdings (AFRM) Still Attractive After Recent Buy Now Pay Later Headlines And Volatility

If you are wondering whether Affirm Holdings at around US$49.77 still offers value or if the big move is already behind it, this article is for you. The stock has had a mixed run recently, with a 4.1% gain over the last 7 days, a 12.7% decline over the past month, a 32.8% decline year to date, a 6.4% gain over the last year, and a very large 3-year return of about 4x. Recent headlines have continued to focus on Affirm's role in the buy now, pay later space, including coverage of its merchant...
NYSE:MTZ
NYSE:MTZConstruction

MasTec (MTZ) Valuation Check After Strong Earnings, 2026 Guidance And Ongoing Profitability Concerns

MasTec (MTZ) is back on investors’ radar after releasing fourth quarter and full year 2025 results, along with fresh 2026 guidance, combining strong reported growth with ongoing questions around margins and cash generation. See our latest analysis for MasTec. MasTec’s latest earnings and 2026 guidance have come alongside strong price momentum, with a 30 day share price return of 15.8% and a year to date gain of 31.8%. The 1 year total shareholder return of 162.2% and 3 year total shareholder...
NYSE:FNB
NYSE:FNBBanks

Is There Now An Opportunity In F.N.B (FNB) After Recent Share Price Weakness

If you are wondering whether F.N.B at around US$16.31 is offering fair value or a potential bargain, looking closely at how it is priced against its fundamentals can be a useful next step. The share price has had mixed recent returns, with a 7 day return of a 4.2% decline, a 30 day return of a 13.7% decline, a year to date return of a 5.1% decline, and a 1 year return of 28.5%, a 3 year return of 44.8% and a 5 year return of 49.0%. Recent coverage has focused on F.N.B as a regional bank...
NasdaqGS:OLED
NasdaqGS:OLEDSemiconductor

Universal Display (OLED) Valuation Check After Extended LG Display Supply And License Agreements

Universal Display (OLED) just extended its long term OLED material supply and license agreements with LG Display, reaffirming a key commercial tie that supports demand for its UniversalPHOLED materials in a crowded OLED market. See our latest analysis for Universal Display. Despite renewing a core agreement with LG Display and recently highlighting progress in white PHOLED lighting, Universal Display’s share price has had a 1 month share price return decline of 20.2% and a 1 year total...
NasdaqGS:MRNA
NasdaqGS:MRNABiotechs

Is It Too Early To Reassess Moderna (MRNA) After Its Strong 2024 Share Price Rally?

If you are wondering whether Moderna's current share price reflects its true worth, you are not alone. Many investors are asking the same question as the market reassesses the mRNA pioneer. The stock recently closed at US$54.98, with returns of 10.3% over 7 days, 34.1% over 30 days and 78.2% year to date, while the 1 year return is 62.9% and the 3 and 5 year returns are 63.7% and 64.8% declines respectively. Recent headlines have focused on Moderna's mRNA platform and its pipeline beyond...
NYSE:BAP
NYSE:BAPBanks

Assessing Credicorp’s Valuation As Revised Dividend Policy And Board Decisions Shape Payout Outlook

Why Credicorp’s revised dividend policy matters now Credicorp (NYSE:BAP) has put dividends at the center of the conversation, formally updating its dividend policy and tying future payouts to a detailed set of financial, legal, and solvency conditions. The move comes alongside a series of past and upcoming board meetings focused on dividend distributions and transfers between retained earnings and reserves, which gives investors fresh information on how the company thinks about capital...
NasdaqCM:IMNM
NasdaqCM:IMNMBiotechs

A Look At Immunome (IMNM) Valuation After Narrower 2025 Loss And New US$156 Million Shelf Registration

Immunome earnings and shelf registration set the stage Immunome (IMNM) has drawn fresh attention after reporting a full year 2025 net loss of US$212.39 million, which was narrower than the prior year, alongside a new shelf registration for up to roughly US$156 million in common stock. See our latest analysis for Immunome. Against this backdrop, Immunome’s share price has been choppy, with a 7.68% 90 day share price return and a 12.14% 30 day share price decline. Yet longer term momentum...
NYSE:CSTM
NYSE:CSTMMetals and Mining

A Look At Constellium (CSTM) Valuation After Strong Recent Share Price Performance

Why Constellium is on investors’ radar today Constellium (NYSE:CSTM) is drawing attention after a strong past 3 months, with the stock showing a 40.5% total return and a 115.3% total return over the past year. For investors tracking industrial materials, that recent performance is prompting a closer look at how Constellium’s $8,449.0 million in revenue and $273.0 million in net income line up with its current share price of $25.49. See our latest analysis for Constellium. At a share price of...
NYSE:VOYG
NYSE:VOYGAerospace & Defense

Voyager Technologies (VOYG) Posts US$116 Million Annual Loss Testing High-Growth Bullish Narratives

Voyager Technologies (VOYG) just closed FY 2025 with Q4 revenue of US$46.7 million and a basic EPS loss of US$0.52. Trailing 12 month revenue came in at US$166.4 million against a full year EPS loss of US$2.89 and revenue growth of 15.4% over the past year. The company has seen quarterly revenue range from US$34.5 million to US$46.7 million this year, with basic EPS losses stretching from US$0.28 to US$3.45 per quarter. Trailing 12 month net income excluding extra items was a loss of US$116.1...
NYSE:OI
NYSE:OIPackaging

A Look At O-I Glass (OI) Valuation After European Headwinds And Cost Savings Update

O-I Glass (OI) recently flagged tougher than expected trading in early 2026, citing softer European demand, temporary supply chain costs from factory closures, and pricing pressure in wine, while still keeping its full year guidance intact. See our latest analysis for O-I Glass. Those softer early 2026 trading conditions and European headwinds help explain why the 30 day share price return sits at a 29.89% decline and the year to date share price return is down 23.09%. At the same time, the 1...
NYSE:BHVN
NYSE:BHVNBiotechs

Assessing Biohaven (BHVN) Valuation After Pipeline Optimism And Supportive Sector Sentiment

Why Biohaven is back on traders' screens Biohaven (BHVN) is back in focus after upbeat analyst commentary on its epilepsy drug opakalim, stronger sentiment following a peer’s Phase 3 epilepsy result, and a sector wide reaction to US regulatory leadership changes. See our latest analysis for Biohaven. Despite a positive 1 day share price return of 0.59% to US$10.27 after the recent analyst commentary and sector tailwinds, Biohaven’s 30 day share price return of 11.47% and 1 year total...
NYSE:WLY
NYSE:WLYMedia

Assessing Wiley (WLY) Valuation After Q3 Profit Rebound AI Growth And Buybacks

John Wiley & Sons (WLY) is back in focus after reporting fiscal third quarter earnings that returned the business to profitability, alongside steady revenue, expanding AI driven research offerings, and active share repurchases. See our latest analysis for John Wiley & Sons. The recent Q3 profit rebound and ongoing buybacks appear to have shifted sentiment, with a 25.21% 1 month share price return and a 24.10% year to date share price return, even though the 1 year total shareholder return is...
NYSE:UHS
NYSE:UHSHealthcare

Is Universal Health Services (UHS) Attractive After Recent Pullback In Share Price

If you are wondering whether Universal Health Services is offering fair value at around US$186.53, you are not alone. This article focuses on what the numbers say about the stock today. The share price has pulled back recently, with an 8.9% decline over the last 7 days and a 14.7% decline over the last 30 days. However, the 1 year and 3 year returns of 8.5% and 62.2% respectively still stand out. Recent news around Universal Health Services has focused on the company as a key player in the...
NYSE:EIX
NYSE:EIXElectric Utilities

Edison Lawsuit Win Refocuses Attention On Wildfire Liabilities And Valuation

Edison International (NYSE:EIX) secured a dismissal of a shareholder lawsuit challenging its wildfire risk disclosures. The case focused on statements made before the January 2025 Los Angeles wildfires. The ruling removes a specific litigation claim tied to how the company communicated wildfire exposure to investors. Edison International, the parent of Southern California Edison, sits at the center of ongoing debates around utility wildfire exposure and risk management in California. The...
NYSE:MO
NYSE:MOTobacco

Evaluating Altria Group (MO) After Recent Share Price Momentum And Mixed Valuation Signals

Altria Group (MO) is back on investors’ radar after recent share price moves, with the stock last closing at $67.14. You might be weighing how its returns and fundamentals currently line up. See our latest analysis for Altria Group. The latest move to $67.14 comes after a 14.4% 90 day share price return and a 17.15% year to date share price return, with a 1 year total shareholder return of 23.74% indicating solid momentum over a longer horizon. If this has you thinking about where else...
NYSE:NWN
NYSE:NWNGas Utilities

Assessing Northwest Natural Holding (NWN) Valuation After A Strong Year Of Shareholder Returns

Event context and recent performance Northwest Natural Holding (NWN) has drawn investor attention after recent trading, with the stock closing at US$51.62 and showing mixed short term moves, including a 1 day decline and a gain over the past month. See our latest analysis for Northwest Natural Holding. That 1 day share price pullback sits against a firmer backdrop, with a 30 day share price return of 7.39%, year to date gain of 10.44%, and a 1 year total shareholder return of 30.13%,...
NasdaqGS:SATS
NasdaqGS:SATSMedia

EchoStar (SATS) Valuation After Spectrum Sale To AT&T And SpaceX And Upcoming EchoStar XXV Launch

EchoStar (SATS) is in the spotlight after selling US$42.65b of spectrum to AT&T and SpaceX. The company is cutting net debt and bankruptcy risk, while preparing the EchoStar XXV launch and reshaping its Pay TV and Broadband operations. See our latest analysis for EchoStar. The share price is at US$108.50 after a 7 day share price return of a 7.19% decline and a 90 day share price return of a 4.35% gain. The 1 year total shareholder return of just over 3x suggests powerful longer term...
NYSE:ALB
NYSE:ALBChemicals

Has Albemarle (ALB) Run Too Far After 134% One-Year Share Price Surge?

Wondering whether Albemarle's current share price gives you a fair deal, or if the market is mispricing the stock? This article focuses on what the numbers say about value rather than the hype. Albemarle's share price last closed at US$166.54, with returns of 1.1% over 7 days, 1.9% over 30 days, 15.7% year to date, 133.9% over 1 year, negative 22.7% over 3 years and 13.4% over 5 years. Taken together, these figures give you a mixed picture of recent and longer term performance. Recent...
NYSE:DG
NYSE:DGConsumer Retailing

Is Dollar General (DG) Still Attractively Priced After Mixed Share Price Performance?

If you are wondering whether Dollar General's share price around its recent US$146 close still offers value, you are not alone. This article is built to help you weigh what that price might actually represent. The stock has had a mixed run, with a 4.6% decline over the last 7 days, a 0.4% decline over 30 days, but a 6.7% gain year to date and an 89.7% return over the past year, set against 3-year and 5-year returns of 28.0% and 18.4% declines respectively. Recent coverage of Dollar General...